1.48 +0.04 (2.76%)
ARNA
| Trade ARNA now with |
Stock Details
Last Trade:1.48 Change:+0.04 (2.76%) Prev Close:1.44 Open: 1.45 Days Range:1.44 – 1.50 52 Week Range: 1.30 - 2.68 Volume:1011062 P/E: N/AEPS:-0.08
View AllRecent Alerts 03/11/17
Recent Alert on 01/05/17 at 9:24am
Pre-Open Stock Movers 01/05: (PIRS) (CTIC) (CEB) Higher; (AEZS) (KSS) (M) Lower (more...)
Pre-Open Stock Movers 01/05: (PIRS) (CTIC) (CEB) Higher; (AEZS) (KSS) (M) Lower (more...)
Today's Pre-Open Stock MoversAeterna Zentaris Inc. (NASDAQ: AEZS) 34.3% LOWER; announced that the confirmatory Phase 3 clinical trial of Macrilen (macimorelin) failed to achieve its objective of validating a single oral dose of macimorelin for the... Read More
Recent Alert on 01/05/17 at 7:27am
Needham & Company Reiterates Hold on Arena Pharma (ARNA) Following Revised Belviq Agreement
Needham & Company Reiterates Hold on Arena Pharma (ARNA) Following Revised Belviq Agreement
Recent Alert on 01/04/17 at 6:07pm
After-Hours Stock Movers 01/04: (ARNA) (ALXN) (SGYP) Higher; (AEZS) (KSS) (M) Lower (more...)
After-Hours Stock Movers 01/04: (ARNA) (ALXN) (SGYP) Higher; (AEZS) (KSS) (M) Lower (more...)
Recent Alert on 01/04/17 at 4:10pm
Arena Pharma (ARNA), Eisai Amend Marketing and Supply Agreement for BELVIQ; Eisai to Acquire Global Commercialization Rights to BELVIQ
Arena Pharma (ARNA), Eisai Amend Marketing and Supply Agreement for BELVIQ; Eisai to Acquire Global Commercialization Rights to BELVIQ
View AllRecent Press Releases
Press Release on 03/08/17 at 4:30pm
Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference
Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 08/06/13 at 8:00am
Arena Pharmaceuticals: Current Prescription Rates Aren't The Real Issue
Arena Pharmaceuticals: Current Prescription Rates Aren't The Real Issue